STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GPCR STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

Market Closed 01-09 16:00:00 EST

68.61

+1.63

+2.43%

盘后69.60

+0.99+1.44%

19:40 EST

High69.78	Low66.59	Vol1.12M
Open66.64	D1 Closing66.98	Amplitude4.76%
Mkt Cap4.74B	Tradable Cap3.36B	Total Shares69.14M
T/O76.78M	T/O Rate2.28%	Tradable Shares49.03M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GPCR","market":"US","secType":"STK","nameCN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","latestPrice":68.61,"timestamp":1767992400000,"preClose":66.98,"halted":0,"volume":1120189,"hourTrading":{"tag":"盘后","latestPrice":69.599,"preClose":68.61,"latestTime":"19:40 EST","volume":53533,"amount":3691949.1964,"timestamp":1768005623127},"delay":0,"floatShares":49026700,"shares":69139200,"eps":-3.652895,"marketStatus":"Market Closed","change":1.63,"latestTime":"01-09 16:00:00 EST","open":66.64,"high":69.78,"low":66.59,"amount":76778426.1734,"amplitude":0.047626,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.652895,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":7,"adr":0,"adrRate":3,"listingDate":1675400400000,"exchange":"NASDAQ","adjPreClose":66.98,"preHourTrading":{"tag":"盘前","latestPrice":67.38,"preClose":66.98,"latestTime":"09:26 EST","volume":1505,"amount":101408.60065,"timestamp":1767968775432},"postHourTrading":{"tag":"盘后","latestPrice":69.599,"preClose":68.61,"latestTime":"19:40 EST","volume":53533,"amount":3691949.1964,"timestamp":1768005623127},"volumeRatio":1.0886687030317836,"impliedVol":0.5882,"impliedVolPercentile":0.0637},"requestUrl":"/m/hq/s/GPCR","defaultTab":"news","newsList":[{"id":"2602318590","title":"Press Release: Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2602318590","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602318590?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:05","pubTimestamp":1767906300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026  -- Septerna, Inc. , a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor  drug discovery, today announced the appointment of Mark A. Wilson as Chief Legal Officer. Mr. Wilson is an accomplished pharmaceutical and biotech executive with more than 25 years of experience across intellectual property, corporate legal, strategic collaborations and corporate governance matters.\"We are thrilled to welcome Mark to the team,\" said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. \"His deep expertise across intellectual property strategy and corporate legal matters will be instrumental as we continue to strengthen our governance framework and maximize the value of our portfolio and proprietary Native Complex Platform. Mark's leadership will be vital as we scale the capabilities needed to execute on our long-term strategy and deliver new medicines for patients.\". \"Septerna represents an ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4099","BK4604","SEPN","BK4007","BK4599","BK4588","GPCR","TM","BK4585","BK4555"],"gpt_icon":0},{"id":"1146401006","title":"Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up 5%; Eli Lilly Rises 4% to Record High; Amgen up 3%; Roche, Novo up Around 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1146401006","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146401006?lang=en_us&edition=fundamental","pubTime":"2026-01-07 23:15","pubTimestamp":1767798955,"startTime":"0","endTime":"0","summary":"Weight-loss drugmakers' stocks jumped on Wednesday. Structure Therapeutics up 5%; Eli Lilly rose 4% to record high; Amgen up 3%; Roche, Novo up around 2%.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Weight-Loss Drugmakers' Stocks Jump. Eli Lilly Rises 4% to Record High","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","AMGN","RHHBY","VKTX","NVO","PFE","LLY"],"gpt_icon":0},{"id":"1123730705","title":"Weight-Loss Drugmakers' Stocks Jump. Arrowhead up over 17%; Structure Therapeutics up over 6%; Novo Nordisk up 5%; Viking, Pfizer, Eli Lilly up Around 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123730705","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123730705?lang=en_us&edition=fundamental","pubTime":"2026-01-06 23:05","pubTimestamp":1767711953,"startTime":"0","endTime":"0","summary":"Weight-loss drugmakers' stocks jumped. Arrowhead up over 17%; Structure Therapeutics up over 6%; Novo Nordisk up 5%; Viking, Pfizer, Eli Lilly up around 2%.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"c7a5ad1f4c9cc897f075885965193731","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFE","RHHBY","LLY","VKTX","NVO","AMGN","GPCR"],"gpt_icon":1},{"id":"2601814858","title":"BRIEF-Structure Therapeutics Inc - Gasherbrum Entered Agreement With Genentech And Roche - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2601814858","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601814858?lang=en_us&edition=fundamental","pubTime":"2026-01-06 06:15","pubTimestamp":1767651351,"startTime":"0","endTime":"0","summary":"BRIEF-Structure Therapeutics Inc - Gasherbrum Entered Agreement With Genentech And Roche - SEC FilingStructure Therapeutics Inc GPCR.O:STRUCTURE THERAPEUTICS INC - GASHERBRUM ENTERED AGREEMENT WITH GENENTECH AND ROCHE - SEC FILINGSTRUCTURE THERAPEUTICS INC - GENENTECH TO PAY GASHERBRUM $100 MILLION - SEC FILINGSource text: [ID:n0001104659-26-000620]Further company coverage: GPCR.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60GL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","BK4007","GPCR"],"gpt_icon":0},{"id":"2601837879","title":"Structure Therapeutics Inc - Genentech to Pay Gasherbrum $100 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2601837879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601837879?lang=en_us&edition=fundamental","pubTime":"2026-01-06 05:09","pubTimestamp":1767647379,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60GL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GPCR","BK4599"],"gpt_icon":0},{"id":"2601683787","title":"Structure Therapeutics Subsidiary Grants Genentech $100 Million License for GLP-1 Patents","url":"https://stock-news.laohu8.com/highlight/detail?id=2601683787","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601683787?lang=en_us&edition=fundamental","pubTime":"2026-01-06 05:08","pubTimestamp":1767647295,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc. announced that its wholly-owned subsidiary, Gasherbrum Bio, Inc., has entered into a material agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. Under the agreement, Gasherbrum has granted Genentech and Roche a non-exclusive, sublicensable, royalty-bearing license to certain patents covering a class of oral GLP-1 receptor agonists distinct from aleniglipron. Genentech will make a one-time, non-refundable payment of $100 million to Gasherbrum and will pay royalties at a low single digit rate on net sales of products containing CT-996, a proprietary compound owned by Genentech. The agreement does not affect Structure Therapeutics’ ongoing programs or grant Genentech any patent prosecution or enforcement rights.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL4Rz0qt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4007","BK4599"],"gpt_icon":0},{"id":"2600708537","title":"The Year-End 2025 Biotech Rally And What It Means For 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2600708537","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600708537?lang=en_us&edition=fundamental","pubTime":"2025-12-31 23:54","pubTimestamp":1767196440,"startTime":"0","endTime":"0","summary":"Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a rocky start to deliver some of the year’s most impressive gains. What began as a sector weighed down by tariff fears and political noise has transformed into one of the market’s standout performers, powered by deal making, drug approvals, and breakthrough clinical results. The big question heading into 2026 is simple: can this momentum last?The performance metrics speak volumes. The iShares Biotechnology ETF  has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF  has done even better with gains around 35.84%. The Nasdaq Biotechnology Index sits at 5,766.59, marking a 34% jump for the year.Regulatory wins provided another boost. The FDA greenlit 44 new therapies in 2025, with 26 approvals coming in the second half alone. December saw notable wins including Cytokinetics Incorporated’s  Myqorzo for a heart condition, marking the company’s first approval after 27 years ","market":"us","thumbnail":"/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/25/12/49650052/the-year-end-2025-biotech-rally-and-what-it-means-for-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/25/12/49650052/the-year-end-2025-biotech-rally-and-what-it-means-for-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU1037948897.HKD","QID",".IXIC","IE00BJT1NW94.SGD","IBB","ITCI","MRK","LU2430703178.SGD","NVIW.SI","LU2089984988.USD","LU0432979614.USD","LU2592432038.USD","GPCR","MNPR","BK4532","IE00B1BXHZ80.USD","PSQ","QLD","BK4581","NVS","NQmain","IONS","SG9999014906.USD","SQQQ","LU1935042991.SGD","IE00BBT3K403.USD","LU0256863811.USD","RNA","USAW.SI","OMER","LU0823434740.USD","USJW.SI","TSYW.SI","LU1116320737.USD","VRNA","IE00BVYPNW00.USD","JNJ","PFE","TQQQ","EYPT","IE0005OL40V9.USD","MNQmain","LU0471298694.HKD","BK4505","LU0306807586.USD","SG9999014880.SGD","CYTK","LU2063271972.USD"],"gpt_icon":1},{"id":"2595777995","title":"BUZZ-Structure Therapeutics doubles while other obesity drug developers decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2595777995","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595777995?lang=en_us&edition=fundamental","pubTime":"2025-12-31 22:29","pubTimestamp":1767191374,"startTime":"0","endTime":"0","summary":"BUZZ-Structure Therapeutics doubles while other obesity drug developers decline ** Shares of Structure Therapeutics GPCR.O have more than doubled this year, after declining 33% in 2024 ** Structure earlier this month said its experimental oral obesity pill showed 11.3% reduction in weight at 120 mg dose at 36 weeks in mid-stage study** Shares of other obesity drug developers such as Viking Therapeutics VKTX.O and Altimmune ALT.O are set to end in red      ** Weight-loss drug market is surging, with biotech firms racing to win share in sector dominated by Novo Nordisk NOVOb.CO and Eli Lilly LLY.N** Analysts forecast the industry will generate about $150 billion in annual sales in the next decade** Shares of Viking are down 12.2% this year after more than doubling in 2024; company said its experimental weight-loss pill helped patients lose 12.2% of their body weight in mid-stage trial, missing Wall Street's top-end expectations of 15%** Shares of Altimmune have fallen 49.9% this year, se","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nL4N3Y10LP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1069344957.HKD","LU2237443382.USD","SG9999018857.SGD","IE00BN29S564.USD","LU0456855351.SGD","LU1983299246.USD","LU0354030438.USD","LU1093756168.USD","LU2237443622.USD","LU2602419157.SGD","LU2750360997.AUD","LU0256863902.USD","LU0823416689.USD","IE00BK4W5M84.HKD","LU0203201768.USD","LU1551013342.USD","BK4599","LU0882574055.USD","LU0889565916.HKD","LU0058720904.USD","LU1035775433.USD","LU1127390331.HKD","LU2237443895.HKD","SG9999014906.USD","LU0323591593.USD","BK4585","BK4516","IE0005OL40V9.USD","IE00BKDWB100.SGD","LU0820561818.USD","SG9999014914.USD","LU0096364046.USD","LU2746668461.USD","IE0004445239.USD","SG9999001176.SGD","LU0823434583.USD","BK4533","IE00B1XK9C88.USD","IE00BKPKM429.USD","LU2265009873.SGD","LU0417517546.SGD","IE00B2B36J28.USD","LU2746668974.SGD","LU1804176565.USD","LU2237438978.USD","IE00BJLML261.HKD","IE00BJJMRZ35.SGD","LU0316494557.USD","LU1323610961.USD","LU1917777945.USD","LU2456880835.USD","LU2471134952.CNY","LU2168563687.JPY","LU0109391861.USD","LU0203202063.USD","LU0198837287.USD","LU1712237335.SGD","IE0002141913.USD","IE00BFSS7M15.SGD","LU0320765059.SGD","LU1720051108.HKD","IE00BWXC8680.SGD","LU1868836914.USD","IE00B775H168.HKD","LU2491050154.USD","LU2750360641.GBP","LU1061106388.HKD","SG9999018865.SGD","LU0114720955.EUR","BK4139","LU1057294990.SGD","LU2168564222.USD","LU2237443465.HKD","LU2360106947.USD","LU1064131342.USD","SGXZ99366536.SGD","LU2361044865.SGD","LU2552382132.HKD","LU0689472784.USD","LU2471134796.USD","LU0820561909.HKD","LU2112291526.USD","LU1551013425.SGD","BK4007","LU1974910355.USD","SGXZ51526630.SGD","LU2461242641.AUD","IE00BFSS8Q28.SGD","LU2417539215.USD","SGXZ81514606.USD","LU2361044949.HKD","LU0683600562.USD","LU0823434740.USD","LU1814569148.SGD","GPCR","SG9999015986.USD","LU1023059063.AUD","LU1548497426.USD","LU2168564065.EUR","LU0289739699.SGD","LU2237443549.SGD","LU2211815571.USD","LU2023250504.SGD","LU0122379950.USD","SG9999015978.USD","LU1988902786.USD","SG9999017495.SGD","LU2108987350.USD","LU0266013472.USD","LU0238689110.USD","LU2491049909.HKD","LU2491050071.SGD","LU0708995401.HKD","LU0256863811.USD","SG9999014898.SGD","LU0109394709.USD","LU1291159041.SGD","LU2236285917.USD","LU0079474960.USD","LU1989771016.USD","IE00BK4W5L77.USD","IE00BJT1NW94.SGD","LU0882574139.USD","LU1868836591.USD","LU0353189763.USD","LU2552382058.USD","LU2089984988.USD","IE00BFTCPJ56.SGD","IE00BJJMRX11.SGD","IE0004445015.USD","LU0786609619.USD","LU0640476718.USD","LU0471298694.HKD","IE00B4R5TH58.HKD","LU2063271972.USD","LU0234572021.USD","IE0009355771.USD","LU1868837300.USD","LU2168564495.EUR","LU2361045086.USD","LU0943347566.SGD","LU1232071149.USD","LU2468319806.SGD","SG9999014880.SGD","BK4534","LU0320765992.SGD","LU2462157665.USD","LU2087625088.SGD","LU0385154629.USD","LU1720051017.SGD","LU0006306889.USD","LU1280957306.USD","LU1623119135.USD","LU0471298777.SGD","LU1868837136.USD","IE00B7KXQ091.USD","LU1093756325.SGD","LU1868836757.USD","LU0106261372.USD","SG9999015945.SGD","BK4588","LU2237443978.SGD","LU2168564149.EUR","LU2471134523.USD","IE00BJJMRY28.SGD","LU1878469433.USD","LU1366192091.USD","SG9999015952.SGD","LU0061475181.USD","LU0466842654.USD","SG9999001176.USD","LU2264538146.SGD","SG9999013999.USD","SGXZ57979304.SGD","LU2471134879.HKD","LU0787776722.HKD","IE00B4JS1V06.HKD","BK4581","IE00B1BXHZ80.USD","LU2552382215.SGD","GB00BDT5M118.USD","LU0094547139.USD","LU1267930730.SGD","LU0432979614.USD","LU2106854487.HKD","LU2324357040.USD","LU2357305700.SGD","LU0672654240.SGD","SGXZ31699556.SGD","LU0097036916.USD","LU0354030511.USD","LU0353189680.USD"],"gpt_icon":0},{"id":"2592674381","title":"Structure Therapeutics Inc. : H.c. Wainwright Raises Target Price to $90 From $60","url":"https://stock-news.laohu8.com/highlight/detail?id=2592674381","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592674381?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:45","pubTimestamp":1766151909,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nAZN4RH4QD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GPCR","BK4599"],"gpt_icon":0},{"id":"2592190039","title":"BUZZ-Obesity pill maker Structure gains after Lilly's pill shows promising trial data","url":"https://stock-news.laohu8.com/highlight/detail?id=2592190039","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592190039?lang=en_us&edition=fundamental","pubTime":"2025-12-18 23:31","pubTimestamp":1766071885,"startTime":"0","endTime":"0","summary":"BUZZ-Obesity pill maker Structure gains after Lilly's pill shows promising trial data** Structure Therapeutics shares GPCR.O up about 3% at $61.80** Eli Lilly LLY.N trial data shows its oral pill, orforglipron, helped patients maintain weight loss after switching from injectable GLP-1 drugs** J.P. Morgan says Lilly's data \"is a good read-across\" for GPCR's oral pill, aleniglipron, whose trial data is due H2 2026** GPCR shares had doubled on Dec 8 after aleni trial data showed weight loss of up to 11.3% after 36 weeks of treatment** Stock now up about 126% YTD, after a 33.5% drop in 2024** JPM thinks both orfo and aleni could be effective options for patients who want to move away from injectables long term  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nL4N3XO17I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2106854487.HKD","LU0316494557.USD","BK4585","IE00B2B36J28.USD","LU1232071149.USD","LU1366192091.USD","LU2211815571.USD","SG9999015978.USD","LU2237443978.SGD","LU2108987350.USD","IE00BK4W5L77.USD","LU2168564495.EUR","LU0320765059.SGD","LU0432979614.USD","SG9999017495.SGD","LU2237443465.HKD","IE00BJJMRY28.SGD","LU1988902786.USD","LU2236285917.USD","LU0114720955.EUR","SG9999013999.USD","SG9999018857.SGD","BK4534","LU0256863902.USD","IE00BFTCPJ56.SGD","LU0708995401.HKD","LU2087625088.SGD","LU0820561909.HKD","LU2357305700.SGD","LU2361045086.USD","LU2168564065.EUR","LU0289739699.SGD","SG9999018865.SGD","LU0354030438.USD","LU0672654240.SGD","SGXZ81514606.USD","LU1974910355.USD","LU0097036916.USD","LU0456855351.SGD","LU1868837300.USD","LU0006306889.USD","LU1057294990.SGD","LU0079474960.USD","LU2168564222.USD","LU0823434583.USD","LU1712237335.SGD","LU2168564149.EUR","BK4516","LU2462157665.USD","LU0238689110.USD","LU2552382132.HKD","LU2237443622.USD","LU2471134796.USD","LU0787776722.HKD","LU1551013425.SGD","LU2417539215.USD","SGXZ99366536.SGD","BK4581","LU0417517546.SGD","LU1804176565.USD","LU2746668461.USD","LU1127390331.HKD","SG9999014906.USD","IE00B7KXQ091.USD","LU2491050154.USD","IE00BJJMRZ35.SGD","LU2063271972.USD","IE00BFSS7M15.SGD","LU2750360997.AUD","LU2089984988.USD","SG9999014880.SGD","IE0004445239.USD","LU2456880835.USD","LU0882574055.USD","LU0943347566.SGD","LU2237443895.HKD","IE0005OL40V9.USD","SGXZ51526630.SGD","LU0353189763.USD","LU1280957306.USD","SG9999014914.USD","LU0234572021.USD","LU0786609619.USD","LU2471134952.CNY","SG9999015945.SGD","LU0882574139.USD","LU0823434740.USD","LU2237443382.USD","LU0889565916.HKD","SG9999014898.SGD","LU1551013342.USD","IE00BN29S564.USD","LU0256863811.USD","LU1814569148.SGD","LU0106261372.USD","LU1917777945.USD","LU0823416689.USD","LU2602419157.SGD","BK4599","LU0385154629.USD","LU2361044865.SGD","LU1989771016.USD","SG9999015952.SGD","LU0471298777.SGD","LU2264538146.SGD","LU2468319806.SGD","LU0640476718.USD","LU0122379950.USD","IE00B4R5TH58.HKD","IE00BKDWB100.SGD","LU2168563687.JPY","LU2552382215.SGD","SG9999001176.USD","LU0471298694.HKD","IE00BWXC8680.SGD","IE00BKPKM429.USD","LU1548497426.USD","LU0683600562.USD","LU1069344957.HKD","GPCR","LU0096364046.USD","LU0466842654.USD","IE00BJJMRX11.SGD","LU1868836914.USD","IE00BJT1NW94.SGD","LU2491049909.HKD","LU1868837136.USD","LU1983299246.USD","LU2265009873.SGD","LU1868836757.USD","LU1291159041.SGD","BK4007","LU2552382058.USD","LU2750360641.GBP","SGXZ57979304.SGD","LU0203201768.USD","LU0354030511.USD","LU1064131342.USD","LU1720051017.SGD","LU0061475181.USD","SG9999001176.SGD","LU1868836591.USD","IE00BK4W5M84.HKD","LU2324357040.USD","LU2461242641.AUD","LU2746668974.SGD","LU0203202063.USD","IE00BJLML261.HKD","LU2471134879.HKD","LU1061106388.HKD","LU0198837287.USD","LU1023059063.AUD","LU2237438978.USD","LU2471134523.USD","LU1035775433.USD","IE00B1BXHZ80.USD","IE00B1XK9C88.USD","SGXZ31699556.SGD","LU0109394709.USD","LU1323610961.USD","LU1267930730.SGD","LU1623119135.USD","LLY","LU2361044949.HKD","LU2112291526.USD","LU0689472784.USD","BK4588","GB00BDT5M118.USD","SG9999015986.USD","IE00BFSS8Q28.SGD","IE0004445015.USD","LU0109391861.USD","LU1093756168.USD","LU1093756325.SGD","LU1720051108.HKD","LU2237443549.SGD","LU2023250504.SGD","LU0323591593.USD","LU0058720904.USD","IE00B775H168.HKD","IE00B4JS1V06.HKD","IE0002141913.USD","LU0320765992.SGD","LU0820561818.USD","LU0094547139.USD","LU2491050071.SGD","BK4533","LU2360106947.USD","LU0266013472.USD","LU0353189680.USD","IE0009355771.USD"],"gpt_icon":1},{"id":"2592150739","title":"BRIEF-Structure Therapeutics Starts Phase 1 Study Of Oral Amylin Agonist ACCG‑2671","url":"https://stock-news.laohu8.com/highlight/detail?id=2592150739","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592150739?lang=en_us&edition=fundamental","pubTime":"2025-12-17 22:38","pubTimestamp":1765982287,"startTime":"0","endTime":"0","summary":"BRIEF-Structure Therapeutics Starts Phase 1 Study Of Oral Amylin Agonist ACCG2671Dec 17 (Reuters) - Structure Therapeutics Inc GPCR.O:STRUCTURE THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL ST","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA5Z08HX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","GPCR"],"gpt_icon":0},{"id":"2592918919","title":"Structure Therapeutics Launches Phase 1 Trial of Oral Amylin Agonist ACCG-2671 for Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2592918919","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592918919?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:30","pubTimestamp":1765978232,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc. has announced the initiation of a Phase 1 clinical study for ACCG-2671, its lead oral small molecule amylin receptor agonist developed for the treatment of obesity. ACCG-2671 was designed to leverage the metabolic benefits of amylin biology in an oral, once-daily small molecule format, with the goal of improving scalability, combinability, and patient access. The Phase 1 trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic activity of ACCG-2671 in both healthy volunteers and individuals with obesity, utilizing single-ascending dose and multiple-ascending dose cohorts. Results from this study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDLbvyFKk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU2095319765.USD","BK4007","BK4588","BK4599","NDAQ","SG9999014021.USD","BK4112","SG9999014013.SGD","IE00BGHQF748.EUR","GPCR","BK4585","LU2210149790.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU2210150020.SGD","LU0314104364.USD","IE00BKPKM429.USD","SG9999014039.USD"],"gpt_icon":0},{"id":"2592918183","title":"Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist Accg-2671 for the Treatment of Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2592918183","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592918183?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:30","pubTimestamp":1765978201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA5Z08HX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GPCR","BK4007","BK4599"],"gpt_icon":0},{"id":"2592642918","title":"Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2592642918","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592642918?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976400,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Dec.  17, 2025   -- Septerna, Inc. , a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor  drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:45 p.m. PT in San Francisco. A live webcast of the presentation will be available in the investors section of the company’s website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation. About SepternaSepterna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform is designed to enable new approaches to GPCR drug discovery and has led to the development o","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/17/3206946/0/en/Septerna-to-Present-at-44th-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1244550577.SGD","LU1548497426.USD","BK4585","BK4588","LU1791710400.SGD","LU1720051017.SGD","LU2089284900.SGD","BK4599","LU0912757837.SGD","LU0267386448.USD","LU0795875086.SGD","LU0158827781.USD","GPCR","LU2028103732.USD","BK4534","LU0106261372.USD","LU2271345857.HKD","LU1720051108.HKD","LU2023251221.USD","LU2347655156.SGD","XBI","LU0158827948.USD","LU1791710582.SGD","SEPN","HCSG","LU2111349929.HKD","LU0106831901.USD","XLV","LABU","BK4127","LU2357305700.SGD","LU2089283258.USD","LU0971096721.USD","LU2133065610.SGD","LU1074936037.SGD","LU0234570918.USD","LU1244550494.USD","LU0320765646.SGD","LU1668664300.SGD","LU0528227936.USD","BK4581","LU0029874061.USD","LU1244550221.USD","LU0314104364.USD","LU1162221912.USD","BK4516","BK4504","LU0882574139.USD","LU0225283273.USD","LU0128526141.USD"],"gpt_icon":0},{"id":"2590505982","title":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505982","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590505982?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:04","pubTimestamp":1765541041,"startTime":"0","endTime":"0","summary":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats upChanges dateline, adds new details in paragraph 19, 20, 27, 36 and 54. The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently dominated by Novo Nordisk NOVOb.CO and Eli Lilly LLY.N.Analysts project the industry could rake in $150 billion in annual sales by the next decade.Soaring demand for its obesity treatment has helped Lilly become the first pharmaceutical company to reach","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL4N3XI0R0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4JS1V06.HKD","LU0256863902.USD","SRRK","IE00BJJMRX11.SGD","LU1989771016.USD","VKTX","LU0499090636.EUR","600196","AMGN","AZN.UK","BK0187","SG9999014906.USD","LLY","LU0130517989.USD","LU1061106388.HKD","LU0306806265.USD","SG9999015986.USD","IE00BN8TJ469.HKD","BK0028","GPCR","BK4566","SG9999002224.SGD","LU1989772840.SGD","03692","LU1720051017.SGD","LU2106854487.HKD","LU1003077747.HKD","02105","ALT","IE0005OL40V9.USD","OPK","LU0106261372.USD","SGXZ99366536.SGD","LU1323610961.USD","00656","MRK","MTSR","SG9999013999.USD","LU1035775433.USD","BK0188","IE0002141913.USD","LU0345777147.USD","LU0211328371.USD","LU0823434583.USD","IE00BJLML261.HKD","03933","IE00BK4W5M84.HKD","LU0964806797.USD","03165"],"gpt_icon":1},{"id":"2590499345","title":"Press Release: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs","url":"https://stock-news.laohu8.com/highlight/detail?id=2590499345","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590499345?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Dec. 11, 2025  -- Structure Therapeutics Inc. , a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the closing of its previously announced upsized underwritten public offering of 9,961,538 American depositary shares , each representing three ordinary shares, which includes the full exercise of the underwriters' option to purchase up to 1,500,000 additional ADSs at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of $64.9999 per pre-funded warrant. All of the securities in the offering were sold by Structure Therapeutics.The gross proceeds to Structure Therapeutics from the offering were approximately $747.5 million, before deducting underwriting discounts and commissions and offering expenses.Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Guggenheim Securities and BMO Ca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1244550221.USD","LU2023251221.USD","LU2111349929.HKD","LU0006306889.USD","LU1989772923.USD","IE00BZ1G4Q59.USD","LU0234570918.USD","LU0106261372.USD","BK4007","BK4139","LENZ","LU1244550494.USD","BK4539","LU0795875086.SGD","LU1720051108.HKD","LU0557290698.USD","LU1548497426.USD","LU0528227936.USD","LU0314104364.USD","LU0795875169.SGD","LU0267386448.USD","LU0320765646.SGD","LU2089283258.USD","LU0106831901.USD","BK4127","LU2089284900.SGD","LU0158827781.USD","LU0882574139.USD","LU1074936037.SGD","BK4588","LU0225283273.USD","LU0098860793.USD","LU1732799900.SGD","LU1720051017.SGD","GPCR","BK4581","BK4534","LU1244550577.SGD","LU1989772840.SGD","LU2028103732.USD","LU2357305700.SGD","LU1668664300.SGD","LU1791710582.SGD","LU0912757837.SGD","BK4504","LU1732800096.USD","LU2271345857.HKD","LU2133065610.SGD","BK4516","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2590182805","title":"Structure Therapeutics Inc : Leerink Partners Raises Target Price to  $90.00 From $44.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2590182805","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590182805?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:02","pubTimestamp":1765454572,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH0YC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","GPCR","BK4007"],"gpt_icon":0},{"id":"2590755847","title":"Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590755847","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590755847?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:01","pubTimestamp":1765400460,"startTime":"0","endTime":"0","summary":"Company will host conference call and live webcast to review and discuss the data at 8:00 am ETNORWOOD, Mass., Dec.  10, 2025  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/10/3203493/0/en/Corbus-Pharmaceuticals-to-Report-Results-from-Phase-1a-Study-of-Oral-CB1-Inverse-Agonist-CRB-913-for-the-Treatment-for-Obesity-on-Thursday-December-11-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GPCR","BK4007","CRBP","BK4599"],"gpt_icon":0},{"id":"1156240464","title":"Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up over 6%; Novo Nordisk, Roche up Nearly 4%; Eli Lilly up Slightly","url":"https://stock-news.laohu8.com/highlight/detail?id=1156240464","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156240464?lang=en_us&edition=fundamental","pubTime":"2025-12-10 23:21","pubTimestamp":1765380091,"startTime":"0","endTime":"0","summary":"Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up over 6%; Novo Nordisk, Roche up nearly 4%; Eli Lilly up slightly.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"519c241caca73867484fcacc01269b1b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFE","GPCR","RHHBY","NVO","AMGN","VKTX","LLY"],"gpt_icon":0},{"id":"2590583775","title":"Structure Therapeutics Prices $650 Million Upsized Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590583775","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590583775?lang=en_us&edition=fundamental","pubTime":"2025-12-10 18:05","pubTimestamp":1765361145,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) said Wednesday it has priced its upsized public offering of about 8.5 million American depositary shares at $65 per ADS.The company also priced pre-funded warrants to pur","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4599","BK4007","BK4539","LENZ","GPCR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.structuretx.com","stockEarnings":[{"period":"1week","weight":0.0072},{"period":"1month","weight":-0.0048},{"period":"3month","weight":1.2817},{"period":"6month","weight":2.6092},{"period":"1year","weight":1.5374},{"period":"ytd","weight":-0.0135}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.053913},{"month":2,"riseRate":0,"avgChangeRate":-0.138732},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.094654},{"month":4,"riseRate":0.666667,"avgChangeRate":0.182978},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.022859},{"month":6,"riseRate":0.666667,"avgChangeRate":0.133478},{"month":7,"riseRate":0,"avgChangeRate":-0.101218},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.04351},{"month":9,"riseRate":1,"avgChangeRate":0.463472},{"month":10,"riseRate":0.666667,"avgChangeRate":0.200398},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.123384},{"month":12,"riseRate":0.333333,"avgChangeRate":0.164068}],"exchange":"NASDAQ","name":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","nameEN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD,GPCR,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票老虎,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票老虎国际,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD行情,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票行情,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股价,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股市,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票价格,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票交易,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票购买,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction